FINGOLIMOD HYDROCHLORIDE

Post-LOE

fingolimod

ANDAORALCAPSULE
Approved
Dec 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of…

Clinical Trials (5)

NCT06408259Phase 3Recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Started Apr 2025
194 enrolled
Multiple Sclerosis, Relapsing-Remitting
NCT05123703Phase 3Active Not Recruiting

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Started May 2022
188 enrolled
Relapsing-Remitting Multiple Sclerosis
NCT05423769N/ACompleted

Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Started Jan 2022
30 enrolled
Relapsing-Remitting Multiple Sclerosis
NCT04926818Phase 3Active Not Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Started Oct 2021
129 enrolled
Multiple Sclerosis (MS)
NCT04667949Phase 4Completed

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Started Feb 2021
98 enrolled
Relapsing Multiple Sclerosis (RMS)